Literature DB >> 11159944

Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death.

L P Weng1, O Gimm, J B Kum, W M Smith, X P Zhou, D Wynford-Thomas, G Leone, C Eng.   

Abstract

The tumour suppressor gene PTEN/MMAC1/TEP1 has been implicated in a variety of human cancers and several inherited hamartoma tumour syndromes, including Cowden syndrome, which has a high risk of breast and thyroid cancer. We have previously reported that overexpression of PTEN in MCF-7 breast cancer cells induces cell cycle arrest and apoptosis. In this study, we analysed PTEN status at both the structural and expression levels and explored PTEN's growth-suppressive effects on thyroid. We found that 1 of 10 thyroid cancer lines [follicular thyroid carcinoma FTC-133] had hemizygous deletion and a splice variant IVS4--19G-->A in the remaining allele. Four lines, including FTC-133, express PTEN mRNA at low levels. In general, PTEN protein levels correlated with mRNA levels, except for NPA87, which has low levels of transcript and relatively high levels of PTEN protein. Transient expression of PTEN in seven thyroid cancer cell lines resulted in G(1) arrest in two well differentiated papillary thyroid cancer lines (PTCs) and both G(1) arrest and cell death in the remaining five lines, including three FTCs, one poorly differentiated PTC and one undifferentiated thyroid cancer. The level of phosphorylated Akt was inversely correlated with the endogenous level of PTEN protein and overexpression of PTEN-blocked Akt phosphorylation in all cells analysed. Our results suggest that downregulation of PTEN expression at the mRNA level plays a role in PTEN inactivation in thyroid cancer and PTEN exerts its tumour-suppressive effect on thyroid cancer through the inhibition of cell cycle progression alone or both cell cycle progression and cell death.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159944     DOI: 10.1093/hmg/10.3.251

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  30 in total

1.  Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing.

Authors:  Lisa Zhang; Mei He; Yaqin Zhang; Naris Nilubol; Min Shen; Electron Kebebew
Journal:  J Clin Endocrinol Metab       Date:  2011-12-14       Impact factor: 5.958

2.  Inhibition of gap junction transfer sensitizes thyroid cancer cells to anoikis.

Authors:  Kirk Jensen; Aneeta Patel; Joanna Klubo-Gwiezdzinska; Andrew Bauer; Vasyl Vasko
Journal:  Endocr Relat Cancer       Date:  2011-09-20       Impact factor: 5.678

3.  Suppression of gastric cancer growth by adenovirus-mediated transfer of the PTEN gene.

Authors:  Ying Hang; Yong-Chen Zheng; Yan Cao; Qing-Shan Li; Yu-Jie Sui
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

4.  Insulin glargine and insulin have identical effects on proliferation and phosphatidylinositol 3-kinase/AKT signalling in rat thyrocytes and human follicular thyroid cancer cells.

Authors:  K Müller; C Weidinger; D Führer
Journal:  Diabetologia       Date:  2010-02-24       Impact factor: 10.122

5.  PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers.

Authors:  Xiao-Ping Zhou; Anu Loukola; Reijo Salovaara; Minna Nystrom-Lahti; Päivi Peltomäki; Albert de la Chapelle; Lauri A Aaltonen; Charis Eng
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

6.  Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults.

Authors:  Xiao-Ping Zhou; Deborah J Marsh; Carl D Morrison; Abhik R Chaudhury; Marius Maxwell; Guido Reifenberger; Charis Eng
Journal:  Am J Hum Genet       Date:  2003-10-17       Impact factor: 11.025

7.  Peroxisome proliferator-activated receptor gamma and retinoic acid receptor synergistically up-regulate the tumor suppressor PTEN in human promyeloid leukemia cells.

Authors:  Young-Rae Lee; Hong-Nu Yu; Eun-Mi Noh; Jong-Suk Kim; Eun-Kyung Song; Myung-Kwan Han; Byeong-Soo Kim; Sung-Ho Lee; Jinny Park
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

8.  Suppression of PTEN expression by NF-kappa B prevents apoptosis.

Authors:  Krishna Murthi Vasudevan; Sushma Gurumurthy; Vivek M Rangnekar
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

9.  Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.

Authors:  Dingxie Liu; Peng Hou; Zhi Liu; Guojun Wu; Mingzhao Xing
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

10.  Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas.

Authors:  N Burrows; J Resch; R L Cowen; R von Wasielewski; C Hoang-Vu; C M West; K J Williams; G Brabant
Journal:  Endocr Relat Cancer       Date:  2010-01-29       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.